European Journal of Pediatrics

, Volume 152, Issue 4, pp 372–374 | Cite as

Intravenous immunoglobulin in two children with Guillain-Barré syndrome

  • L. D. Notarangelo
  • M. Duse
  • S. Tiberti
  • B. Guarneri
  • A. Brunori
  • A. Negrini
  • A. G. Ugazio


Two children with Guillain-Barrè syndrome were succesfully treated with high-dose intravenous immunoglobulin (IVIG) and no relapses occurred over a 1 year follow up. No side-effects were observed. These data provide further evidence that IVIG may be safely and effectively employed in children with Guillain-Barrè syndrome.

Key words

Guillain-Barrè syndrome Intravenous immunoglobulin 





Forged vital capacity


Guillain-Barrè syndrome


Intravenous immunoglobulins


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cook JD, Delgado MR, Soutter-Glass D (1987) Treatment of childhood autoimmune polyneuropathy: III. Gammaglobulin. Neurology 37 [Suppl]:253Google Scholar
  2. 2.
    Eibl M, Wedgwood R (1989) Intravenous Immunoglobulin: a review. Immunodeficiency Rev1 [Suppl]:1–42Google Scholar
  3. 3.
    Harrison BM, Hansen LA, Polland JD, et al (1984) Demyelination induced by serum from patients with Guillain-Barrè syndrome. Ann Neurol 15:163–170Google Scholar
  4. 4.
    Harvey GK, Pollard JD, Schindhelm K, McLeod JG (1989) Experimental allergic neuritis: effect of plasma infusions. Clin Exp Immunol 76:452–457Google Scholar
  5. 5.
    Imbach P, D'Apuzzo V, Hirt A, Rossi E, Vest M, Barandun S, Banmgartner C, Morell A, Schoni M, Wagner HP (1981) High dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet I:1228–1230Google Scholar
  6. 6.
    Kleyweg RP, Van der Mechè FGA, Meulstee J (1988) Treatment of Guillain-Barrè syndrome with high dose gammaglobulin. Neurology 38:1639–1641Google Scholar
  7. 7.
    Koski CL, Humphrey R, Shin ML (1985) Anti-peripheral myelin antibody in patients with demyelinating neuropathy: quantitative and kinetic determination of serum antibody by complement component 1 fixation. Proc Natl Acad Sci USA 82: 905–909Google Scholar
  8. 8.
    Koski CL, Gratz E, Sutherland J, Mayer RF (1986) Clinical correlation with antiperipheral nerve myelin antibodies in Guillain-Barrè syndrome. Ann Neurol 19:573–577Google Scholar
  9. 9.
    Mauro G (1989) Un cas de syndrome de Guillain-Barrè traitè par fortes doses d'immunoglobulin par voie intraveineuse. Rev Neurol 10:731–732Google Scholar
  10. 10.
    Osterman PO, Fagius J, Safwenberg J, et al (1986) Early relapses after plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet II:1161Google Scholar
  11. 11.
    Paine RS, Oppe TE (1966) Neurological examination of children. Medical Books Ltd., London, p 152Google Scholar
  12. 12.
    Robbins SL, Cotran RS (1979) Pathologic bases of disease. WB Saunders, Philadelphia, pp 1581–1582Google Scholar
  13. 13.
    Ropper A, Albers JW, Addison R (1988) Limited relapse in Guillain-Barrè syndrome after plasma exchange. Arch Neurol 45:314–315Google Scholar
  14. 14.
    Salama A, Mueller-Eckhardt C, Kiefel V (1983) Effect of intravenous immunoglobin in immune thrombocytopenia. Lancet II:193–195Google Scholar
  15. 15.
    Schwartz SA (1990) Intravenous immunoglobulin (IVIG) for the therapy of autoimmune disorders. J Clin Immunol 10:81–89Google Scholar
  16. 16.
    Shahar E, Murphy EG, Roifman CM (1990) Benefit of intravenously administered immune serum globulin in patients with Guillain-Barrè syndrome. J Pediatr 116:141–144Google Scholar
  17. 17.
    Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger VE (1984) Anti-idiotypic suppression of autoantibodies to factor VIII (anti-emophilic factor) by high-dose intravenous gamma-globulin. Lancet II:765–768Google Scholar
  18. 18.
    Van der Mechè FGA (1990) The effect of high dose immuno-globulin acute and chronic inflammatory demyelinating poly-neuropathy. In: Intravenous immunoglobulin: Prevention and treatment of disease. Proceedings of NIH Consensus Development Conference on intravenous immunoglobulin (May 21–23, 1990). National Institutes of Health Ed., Bethesda, MD, USA, pp 139–146Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • L. D. Notarangelo
    • 1
  • M. Duse
    • 1
  • S. Tiberti
    • 2
  • B. Guarneri
    • 3
  • A. Brunori
    • 1
  • A. Negrini
    • 1
  • A. G. Ugazio
    • 1
  1. 1.Department of PaediatricsUniversity of BresciaBresciaItaly
  2. 2.Department of Paediatric Neurology and PsychiatryChild HospitalBresciaItaly
  3. 3.Unit of NeurophysiologySpedali CiviliBresciaItaly

Personalised recommendations